CYTK vs. BGNE, GMAB, VTRS, ITCI, SMMT, MRNA, RDY, CTLT, SRPT, and QGEN
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Cytokinetics vs.
Cytokinetics (NASDAQ:CYTK) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Cytokinetics currently has a consensus target price of $83.64, suggesting a potential upside of 82.87%. BeiGene has a consensus target price of $253.69, suggesting a potential upside of 0.00%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than BeiGene.
Cytokinetics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
In the previous week, Cytokinetics had 7 more articles in the media than BeiGene. MarketBeat recorded 10 mentions for Cytokinetics and 3 mentions for BeiGene. Cytokinetics' average media sentiment score of 0.43 beat BeiGene's score of 0.41 indicating that Cytokinetics is being referred to more favorably in the media.
Cytokinetics received 262 more outperform votes than BeiGene when rated by MarketBeat users. Likewise, 79.78% of users gave Cytokinetics an outperform vote while only 69.07% of users gave BeiGene an outperform vote.
48.5% of BeiGene shares are owned by institutional investors. 3.4% of Cytokinetics shares are owned by insiders. Comparatively, 7.4% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cytokinetics has higher earnings, but lower revenue than BeiGene. Cytokinetics is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.
BeiGene has a net margin of -25.94% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat BeiGene's return on equity.
Summary
Cytokinetics beats BeiGene on 12 of the 17 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
This page (NASDAQ:CYTK) was last updated on 1/20/2025 by MarketBeat.com Staff
